Today's Breaking News
- STORM Therapeutics doses first patient with oral METTL3 targeting drug candidate in a solid tumor Phase 1 study
- AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Moderate to Severe Active Crohn's Disease
- uniQure announces FDA approval of first gene therapy for adults with hemophilia B
Latest R&D and Business News
- Lyvgen Announces Phase 2 Clinical Collaboration with Bristol Myers Squibb to Evaluate LVGN7409 in Combination with Nivolumab in Non-Small Cell Lung Cancer Patients
- Novartis and Medicines for Malaria Venture announce decision to move to Phase 3 study for novel ganaplacide/lumefantrine-SDF combination in adults and children with malaria
- Acticor Biotech: World’s First Clinical Trial to Test New Drug Glenzocimab for Heart Attacks
- Takeda’s Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Granted Priority Review by U.S. Food and Drug Administration
- argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review
- Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC)
- Morphic Announces Initiation of EMERALD-2 Phase 2b Clinical Trial of MORF-057 in Patients with Moderate-to-Severe Ulcerative Colitis
- OliX Pharmaceuticals Publishes Preclinical Research Demonstrating OLX104C’s Potential as an Effective Treatment for Hair Loss
- Lantern Pharma Announces Positive Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-184 for Glioblastoma at the Society for Neuro-Oncology Annual Meeting
- Bayer advances Radiology development portfolio and fosters innovation in AI
- Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy in Second Line Recurrent or Metastatic Cervical Cancer Irrespective of PD-L1 Expression Level or Tumor Histology
- GSK provides an update on Blenrep (belantamab mafodotin-blmf) US marketing authorisation